Citatuzumab bogatox
Citatuzumab bogatox (pronunciation: si-ta-tu-zu-mab bo-ga-tox) is a monoclonal antibody designed for the treatment of various types of cancer. It is a biopharmaceutical product that is still in the experimental stages of development.
Etymology
The name 'Citatuzumab bogatox' is derived from the Latin 'citat', meaning 'quickly', and 'bogatox', a term coined by the developers to represent the toxin component of the drug. The 'mab' at the end of the name is a common suffix for monoclonal antibodies.
Mechanism of Action
Citatuzumab bogatox works by targeting specific antigens found on the surface of cancer cells. Once the antibody binds to these antigens, it delivers a toxin that kills the cancer cell. This targeted approach is designed to minimize damage to healthy cells.
Related Terms
See Also
External links
- Medical encyclopedia article on Citatuzumab bogatox
- Wikipedia's article - Citatuzumab bogatox
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski